A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture

Takuya Tada; Chen Fan; Ramanjit Kaur; Kenneth A Stapleford; Harry Gristick; Crina Nimigean; Nathaniel R Landau.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-300319

Documentos relacionados

  1. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
  2. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
  3. Molecular insights and optimization strategies for the competitive binding of engineered ACE2 proteins: a multiple replica molecular dynamics study.
  4. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.
  5. Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality.
  6. In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain.
  7. The puzzling mutational landscape of the SARS-2-variant Omicron.
  8. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern.
  9. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity.
  10. D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity.